Top analysts on stock perps · Analyst
Chris Schott (J.P. Morgan): analyst track record on stock perps
Chris Schott of J.P. Morgan on companies with stock perpetual futures: star rating, success rate, price-target accuracy, current calls and the measured perp reaction after each rating.
Stars4.5★
Success60%
Excess return+6.9%
rank#1,208
Ratings412
ratings on stock perps247
Track record
TipRanks data via FMP| 12 months | 3 years | |
|---|---|---|
| Ratings | 161 | 364 |
| Stock | 43 | 43 |
| Buy / hold / sell | 117 / 42 / 2 | 240 / 117 / 7 |
| Upgrades / downgrades / initiations | 4 / 1 / 0 | 10 / 2 / 1 |
| Price targets hit / missed | 49 / 92 (35%) | 137 / 170 (45%) |
| Avg. return after a rating (TipRanks) | -6.0% | +7.2% |
| Best / worst call | +48.2% / -60.3% | +277.3% / -65.5% |
After buy calls: median 21-day move +2.0% · vs S&P 500 -0.1% (n = 136) · targets hit within a year 67% (n = 72)
Current calls on stock perps
| Stock | Call | Target | vs last close | Date |
|---|---|---|---|---|
| $BIIB Biogen Inc. | Buy · Upgraded | $300 | +19.7% | Oct 12, 2026 |
| $LLY Eli Lilly and Company | Buy · Maintained | $1,500 | +17.8% | Oct 9, 2026 |
| $PFE Pfizer Inc. | Hold · Reiterated | $30.00 | -0.1% | Oct 9, 2026 |
| $ABBV AbbVie Inc. | Buy · Reiterated | $300 | +5.0% | Oct 8, 2026 |
| $BMY Bristol Myers Squibb | Buy · Maintained | $73.00 | +18.7% | Oct 8, 2026 |
| $GILD Gilead Sciences, Inc. | Buy · Maintained | $170 | +8.9% | Oct 7, 2026 |
| $REGN Regeneron Pharmaceuticals, Inc. | Buy · Reiterated | $950 | +18.0% | Oct 6, 2026 |
| $MRK Merck & Co., Inc. | Buy · Maintained | $165 | +13.6% | Oct 5, 2026 |
| $JNJ Johnson & Johnson | Hold · Maintained | $285 | +8.0% | Sep 29, 2026 |
| $AMGN Amgen Inc. | Hold · Maintained | $350 | -20.3% | Aug 6, 2026 |
Recent ratings
- Oct 12, 2026 $BIIB: Upgraded · Buy · $300 · article
- Oct 9, 2026 $LLY: Maintained · Buy · $1,500 · article
- Oct 9, 2026 $PFE: Reiterated · Hold · $30.00 · article
- Oct 9, 2026 $PFE: Maintained · Hold · $30.00
- Oct 8, 2026 $BMY: Maintained · Buy · $73.00 · article
- Oct 8, 2026 $ABBV: Reiterated · Buy · $300 · article
- Oct 7, 2026 $GILD: Maintained · Buy · $170 · article
- Oct 6, 2026 $REGN: Reiterated · Buy · $950 · article
- Oct 5, 2026 $MRK: Maintained · Buy · $165 · article
- Oct 5, 2026 $MRK: Maintained · Buy · $165 · article
- Sep 29, 2026 $JNJ: Maintained · Hold · $285 · article
- Sep 29, 2026 $JNJ: Maintained · Hold · $285 · article
- Sep 28, 2026 $LLY: Maintained · Buy · $1,500 · article
- Sep 25, 2026 $JNJ: Maintained · Hold · $270 · article
- Sep 25, 2026 $REGN: Maintained · Buy · $900 · article
- Sep 25, 2026 $JNJ: Maintained · Hold · $270
- Sep 25, 2026 $ABBV: Maintained · Buy · $285 · article
- Sep 25, 2026 $ABBV: Maintained · Buy · $285
- Sep 24, 2026 $PFE: Maintained · Hold · $28.00 · article
- Sep 25, 2026 $PFE: Maintained · Hold · $28.00 · article
Chris Schott4.5★ · 60% success · +6.9% excess return · TipRanks data via FMP · Source headlines via TheFly/StreetInsider (FMP). Reaction = venue-median perp move after our detection — an observation, not investment advice.